You are here: Industry Insights > AstraZeneca

News List

AstraZeneca India, Business Sweden launch ‘Unnati Healthcare 2.0 – Innovation Challenge’ expressbpd
November 20, 2018
AstraZeneca Pharma India and Business Sweden – The Swedish Trade and Invest Council announced the launch of ‘Unnati Healthcare 2.0- An Innovation Challenge. This challenge, which has been launched for the first time, aims to encourage innovative solutio
Setback for AZ’ Imfinzi lung cancer combination pharmatimes
November 20, 2018
AstraZeneca’s Imfinzi has failed to show a significant benefit over standard of care (SoC) chemotherapy on overall survival in certain patients with lung cancer.
AstraZeneca's Imfinzi immunotherapy combo fails to show benefit in lung cancer pharmafile
November 19, 2018
AstraZeneca has revealed that its immunotherapy combo of Imfinzi (durvalumab) and tremelimumab failed to meet its primary endpoint in a recent
AstraZeneca begins succession planning for CEO Soriot: report firstwordpharma
November 19, 2018
AstraZeneca has started looking for candidates to succeed CEO Pascal Soriot amid pressure from shareholders, reported the Sunday Times without citing sources.
AstraZeneca’s Imfinzi alone and in combination fails in Stage IV lung cancer trial pharmaceutical-technology
November 19, 2018
AstraZeneca has announced its Phase III MYSTIC trial of Imfinzi alone and Imfinzi combined with tremelimumab in untreated non-small cell lung cancer (NSCLC) patients failed to meet its primary endpoint.
AstraZeneca's Imfinzi immunotherapy combo fails to show benefit in lung cancer pharmafile
November 19, 2018
AstraZeneca has revealed that its immunotherapy combo of Imfinzi (durvalumab) and tremelimumab failed to meet its primary endpoint in a recent Phase 3 trial in the treatment
Elpis Biomed Wins Cambridge Start-Up of the Year b3cnewswire
November 17, 2018
Elpis Biomed Ltd. (Elpis), a University of Cambridge spin-out developing high quality human cells via its proprietary OPTi-OX platform, is pleased to announce that the Company has been selected as winner in the category Start-Up of the Year at the 2018 Ca
Elpis Biomed Wins Cambridge Start-Up of the Year b3cnewswire
November 17, 2018
Elpis Biomed Ltd. (Elpis), a University of Cambridge spin-out developing high quality human cells via its proprietary OPTi-OX platform, is pleased to announce that the Company has been selected as winner in the category Start-Up of the Year at the 2018 Ca
Sobi to buy US rights to AstraZeneca’s Synagis drug for $1.5bn pharmaceutical-technology
November 15, 2018
Swedish biopharmaceutical firm Swedish Orphan Biovitrum (Sobi) has signed agreements to acquire the rights to AstraZeneca’s Synagis (palivizumab) medicine in the US for an upfront payment of $1.5bn.
AstraZeneca Sells Infant Drug Rights for $1.5B contractpharma
November 14, 2018
AstraZeneca Sells Infant Drug Rights for $1.5B

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page